377 related articles for article (PubMed ID: 29786075)
1. TP53 gain-of-function mutation promotes inflammation in glioblastoma.
Ham SW; Jeon HY; Jin X; Kim EJ; Kim JK; Shin YJ; Lee Y; Kim SH; Lee SY; Seo S; Park MG; Kim HM; Nam DH; Kim H
Cell Death Differ; 2019 Mar; 26(3):409-425. PubMed ID: 29786075
[TBL] [Abstract][Full Text] [Related]
2. Biallelic TP53 gain of function mutations in rapidly progressing solid tumors.
Sande CM; Chang B; Monga V; Bossler AD; Ma D
Cancer Genet; 2018 Apr; 222-223():20-24. PubMed ID: 29666004
[TBL] [Abstract][Full Text] [Related]
3. Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.
Kazantseva M; Eiholzer RA; Mehta S; Taha A; Bowie S; Roth I; Zhou J; Joruiz SM; Royds JA; Hung NA; Slatter TL; Braithwaite AW
J Pathol; 2018 Sep; 246(1):77-88. PubMed ID: 29888503
[TBL] [Abstract][Full Text] [Related]
4. The role of TP53 gain-of-function mutation in multifocal glioblastoma.
Olafson LR; Gunawardena M; Nixdorf S; McDonald KL; Rapkins RW
J Neurooncol; 2020 Mar; 147(1):37-47. PubMed ID: 32002804
[TBL] [Abstract][Full Text] [Related]
5. A new method of identifying glioblastoma subtypes and creation of corresponding animal models.
Zhou X; Li G; An S; Li WX; Yang H; Guo Y; Dai Z; Dai S; Zheng J; Huang J; Iavarone A; Zhao X
Oncogene; 2018 Aug; 37(35):4781-4791. PubMed ID: 29769617
[TBL] [Abstract][Full Text] [Related]
6. Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties.
Nakayama M; Hong CP; Oshima H; Sakai E; Kim SJ; Oshima M
Nat Commun; 2020 May; 11(1):2333. PubMed ID: 32393735
[TBL] [Abstract][Full Text] [Related]
7. Sex- and mutation-specific p53 gain-of-function activity in gliomagenesis.
Rockwell NC; Yang W; Warrington NM; Staller MV; Griffith M; Griffith OL; Gurnett CA; Cohen BA; Baldridge D; Rubin JB
Cancer Res Commun; 2021 Dec; 1(3):148-163. PubMed ID: 34957471
[TBL] [Abstract][Full Text] [Related]
8. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
9. Establishment and validation of an immune-based prognostic score model in glioblastoma.
Qin Z; Zhang X; Chen Z; Liu N
Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
[TBL] [Abstract][Full Text] [Related]
10. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
[TBL] [Abstract][Full Text] [Related]
11. Hairless regulates p53 target genes to exert tumor suppressive functions in glioblastoma.
Brook L; Palade P; Maatough A; Whitfield GK; Emeterio LS; Hsieh D; Hsieh JC
J Cell Biochem; 2019 Jan; 120(1):533-543. PubMed ID: 30191601
[TBL] [Abstract][Full Text] [Related]
12. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.
Zheng H; Ying H; Yan H; Kimmelman AC; Hiller DJ; Chen AJ; Perry SR; Tonon G; Chu GC; Ding Z; Stommel JM; Dunn KL; Wiedemeyer R; You MJ; Brennan C; Wang YA; Ligon KL; Wong WH; Chin L; DePinho RA
Nature; 2008 Oct; 455(7216):1129-33. PubMed ID: 18948956
[TBL] [Abstract][Full Text] [Related]
13. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
14. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
15. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
Wang X; Chen JX; Liu JP; You C; Liu YH; Mao Q
Ann Surg Oncol; 2014 Apr; 21(4):1337-44. PubMed ID: 24248532
[TBL] [Abstract][Full Text] [Related]
16. Gain-of-Function p53 Mutation Acts as a Genetic Switch for TGFβ Signaling-Induced Epithelial-to-Mesenchymal Transition in Intestinal Tumors.
Wang D; Nakayama M; Hong CP; Oshima H; Oshima M
Cancer Res; 2024 Jan; 84(1):56-68. PubMed ID: 37851521
[TBL] [Abstract][Full Text] [Related]
17. Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
Meng X; Yang S; Li Y; Li Y; Devor EJ; Bi J; Wang X; Umesalma S; Quelle DE; Thiel WH; Thiel KW; Leslie KK
Dis Markers; 2018; 2018():3810108. PubMed ID: 30647797
[TBL] [Abstract][Full Text] [Related]
18. Ionizing radiation-induced gene expression changes in TP53 proficient and deficient glioblastoma cell lines.
Godoy PR; Mello SS; Magalhães DA; Donaires FS; Nicolucci P; Donadi EA; Passos GA; Sakamoto-Hojo ET
Mutat Res; 2013 Aug; 756(1-2):46-55. PubMed ID: 23817105
[TBL] [Abstract][Full Text] [Related]
19. MCP-1 and MIP-3α Secreted from Necrotic Cell-Treated Glioblastoma Cells Promote Migration/Infiltration of Microglia.
Jung Y; Ahn SH; Park H; Park SH; Choi K; Choi C; Kang JL; Choi YH
Cell Physiol Biochem; 2018; 48(3):1332-1346. PubMed ID: 30048972
[TBL] [Abstract][Full Text] [Related]
20. TP53 deleted cells in de novo glioblastomas using fluorescence in situ hybridization.
Horiguchi H; Sano T; Hirose T
Pathol Int; 2001 Mar; 51(3):187-92. PubMed ID: 11328534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]